Micot Pharma's MT200605 Hits Phase II Primary Endpoint in Acute Ischemic Stroke, Offering First-in-Class Multi-Stage Neuroprotection
核心洞察
MT200605, a novel small-molecule BDNF/TrkB (搜索) pathway agonist, met its primary endpoint in a 360-patient Phase II trial for acute ischemic stroke (搜索), with the high-dose group more than doubling the proportion of patients achieving mRS 0–1 at 90 days versus placebo.
The drug employs a globally unique three-stage mechanism—improving blood flow, limiting acute oxidative injury, and promoting neural repair—making it the only clinical-stage neuroprotectant with this integrated approach.
No serious drug-related adverse events were reported, and grade 3+ treatment-emergent adverse events were evenly distributed across groups, indicating a favorable safety profile.
On August 3, 2026, Shaanxi Micot Pharmaceutical Technology Co., Ltd. (搜索) (Micot Pharma; 2335.HK) announced that MT200605, its proprietary drug candidate for acute ischemic stroke (搜索) (AIS), achieved the primary endpoint with statistically significant results in a Phase II clinical trial. The announcement marks a rare positive signal in a therapeutic field that has seen widespread clinical failures for neuroprotective agents.
The multicenter, randomized, double-blind, placebo-controlled study enrolled 360 subjects with acute ischemic stroke (搜索). The primary efficacy endpoint measured the proportion of patients achieving a modified Rankin Scale (mRS) score of 0–1 at 90 days. Both the medium- and high-dose MT200605 groups outperformed placebo, with the high-dose group demonstrating a proportion of patients achieving mRS 0–1 that was more than double that of the placebo group—a statistically significant between-group difference. Consistent efficacy trends were also observed across secondary endpoints.
Throughout the trial, no serious adverse events related to the investigational drug were reported. Treatment-emergent adverse events of grade 3 or higher were evenly distributed among the groups, and no new safety risks were identified, indicating overall good tolerability.
A Globally Unique Three-Stage Mechanism of Action
MT200605's core differentiation lies in what the company describes as the only clinical-stage small-molecule agonist capable of crossing the blood-brain barrier, targeting the BDNF/TrkB (搜索) pathway, and exerting neurorestorative activity. The drug intervenes across three distinct stages of ischemic brain injury through a single molecule:
- Upstream – improving blood flow: MT200605 modulates calcium signaling in vascular smooth muscle to induce vasodilation, relieve secondary ischemia caused by microvascular spasm, improve microcirculation, and enhance cerebral perfusion.
- Midstream – limiting acute injury: The compound potently scavenges reactive oxygen species (ROS) to limit oxidative injury and activates TrkB to attenuate excitotoxicity and reduce neuronal apoptosis, helping rescue threatened neurons in the ischemic penumbra.
- Downstream – promoting repair: Sustained TrkB activation mimics endogenous brain-derived neurotrophic factor (BDNF), initiating repair programs including synaptogenesis, axonal regeneration, and neural network remodeling to support functional recovery.
Compared to existing therapies that block damage through single or dual targets, MT200605 establishes a therapeutic cascade of "blood flow improvement – cellular protection – neural restoration." The company states it holds the potential to become the first neuroprotectant in China to receive Class I recommendation and Level A evidence in clinical guidelines.
Addressing a Massive Unmet Clinical Need
The Global Burden of Disease study reports approximately 7.8 million incident cases of ischemic stroke globally in 2021. In China alone, the total number of stroke patients exceeds 26 million, with roughly 4 million new cases annually. The Global Stroke Report 2025 projects that combined direct medical costs and productivity losses from stroke will surpass $1.8 trillion by 2050, up from $890 billion in 2021.
Currently, no neuroprotective agent has been approved for acute ischemic stroke (搜索) in Europe or the United States. In China, existing neuroprotectants such as butylphthalide and edaravone/edaravone dexborneol hold only Level II recommendations with Grade B evidence according to the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023. These therapies focus solely on damage control without pathways for synchronous neurological restoration.
Growing Recognition and Regulatory Momentum
MT200605 has accumulated significant external validation. In May 2026, the drug was selected for China's National Science and Technology Major Project for Innovative Drug Development, placing it among the few domestic neuroprotective candidates with national-level project endorsement. In March 2026, the US FDA granted Orphan Drug Designation for MT200605 in Huntington's disease (搜索), providing policy support for broader neurological applications.
The organizing committee of the 18th World Stroke Congress (WSC 2026) has also accepted the company's abstract, titled "MT200605: A Novel Bifunctional Neuroprotectant for Ischemic Stroke," for oral presentation. Micot Pharma will present non-clinical and Phase I results to global stroke experts, completing what the company describes as a critical closed loop across "National Strategic Support – International Regulatory Recognition – Top-tier Academic Validation."
With the Phase II primary endpoint met, MT200605's differentiated mechanism has demonstrated positive clinical signals for the first time, positioning it as a potential first-in-class candidate in China's cerebrovascular innovative drug sector.